By Bernard Groen 
As the diabetes community counts down to the 61st EASD Annual meeting in Vienna, excitement is building across digital channels. Using our unique technology, CREATION Pinpoint®, we analysed approximately 300 posts from 150 verified healthcare professionals (HCPs) talking about EASD 2025 over the past three months. Their conversations reveal not only the anticipation for groundbreaking science but also the themes they expect to dominate discussions on stage, from new consensus insights to digital innovations and patient-centred initiatives. In this article, we explore how HCPs are shaping the conversation ahead of EASD 2025, and what this means for leaders across the pharmaceutical and healthcare landscape.
Anticipation ahead of EASD 2025 is gaining pace
Attendees are encouraged to participate in the plethora of sessions. This meeting aims to foster collaboration and knowledge exchange among healthcare professionals, researchers, and advocates in the field of diabetes care. For example both Dr Vinayak S Hiremath (@DrVinayal5555) a prominent endocrinologist based in India, and Othmar Moser (LinkedIn), who is professor of exercise physiology and metabolism based in Germany, both shared their excitement ahead of the annual meeting, with both posts receiving nearly 2,000 impressions.
✨ Honored to be invited as Faculty at the 61st EASD Annual Meeting 2025, Vienna – the world’s most prestigious platform in the field of diabetes.
To be among such an elite community of innovators, researchers, and authors whose work shapes global guidelines and textbooks is… pic.twitter.com/O7lE77aXGP
— ᴅʀ ᴠɪɴᴀʏᴀᴋ s ʜɪʀᴇᴍᴀᴛʜ 🇮🇳 (@DrVinayak5555) September 10, 2025
ADA-EASD consensus insights
Recent HCP discussions highlight the ADA-EASD consensus on the benefits of combining basal insulin with GLP-1 receptor agonists. This combination therapy was noted back in 2018 already, for its superior glycemic control compared to monotherapy, alongside reduced weight gain and lower risks of hypoglycemia. Such insights can be crucial for advancing treatment strategies in Type 2 diabetes management, emphasizing the importance of integrated care approaches in improving patient outcomes. We found that Dr Viswanathan Mohan (@drmohanv), one of the most prominent diabetologists in India, who shared an insightful post which references the results of this combination therapy, which he has been studying, in collaboration with Sanofi (@sanofi), in India his post had reached over 5,000 impressions and he will be presenting the findings of his study during EASD 2025 in his session.
Innovations in diabetes care
The EASD 2025 meeting will feature a variety of symposiums and discussions focused on innovative diabetes care strategies, including the integration of digital health technologies, sometimes these impacts are felt keenly outside the direct field of diabetes, as a study by Dr Andrew J. Barkmeier (@AndrewBarkmeier), a prominent ophthalmologist at the Mayo Clinic, shows improvements derived from patients taking GLP-1 drugs to improve their eye-health. These results were directly shared by Dr Javier Escalada (@fjavesc), who is an endocrinologist based in Spain, emphasised results with his posts gathering 1200 views and reaching more than 4000 people.
Good news for patients using GLP-1 receptor agonists 😃
No retinopathy risk found with GLP-1 drugs in new study https://t.co/oamudRDUZR @diabeteSEEN @ObesitySeen @SEDiabetes @SociedadSeedo @EASOobesity @EASDnews— Javier Escalada #Yoelijoendocrino (@fjavesc) August 8, 2025
Patient-Centered Initiatives
The #dedoc° voices initiative, which supports diabetes advocates to attend EASD, will be prominently featured at this year’s congress, highlighting the importance of patient perspectives in diabetes care. Participants at EASD 2025 are encouraged to engage with the #dedoc° community, to amplify the voices of those living with diabetes. This initiative underscores the need for a patient-centered approach in diabetes management, fostering dialogue between patients and healthcare professionals. These efforts were highlighted by a variety of HCPs including by Claire Howells RNLD (@ClaireHowells10), who is a registered learning disability nurse working with diabetes patients in the community in the Midlands in the UK.
"I am attending EASD 2025 as a #dedoc° voice. The #dedoc° voices scholarship program has facilitated my access. All words are my own."
•
I will be tweeting from the 61st annual meeting from 16th – 19th September.#dedoc, #voices, #EASD2025 pic.twitter.com/YZo9GRLMRg— Claire Howells RNLD (@ClaireHowells10) September 2, 2025
Key Topics at EASD 2025
The EASD 2025 congress will also address a wide variety of critical topics such as hypoglycemia management and the role of continuous ketone monitoring in diabetes care. EASD expects 17,000 – 18,000 participants from over 100 countries worldwide, with experts presenting their findings and insights on these subjects, contributing to the ongoing discourse on best practices in diabetes management.
The event promises to be a platform for sharing knowledge and advancing clinical practices in the field. One way this is done is by the awarding of EASD prizes such as the prize was shared by Dr Daniel J Drucker (@DanielJDrucker), professor of endocrinology at the University of Toronto, and one of the most influential DOLs based on our unique DOL Impact rating, his post highlighting the groundbreaking efforts of Dr Gerald I Shulman, who Professor of Medicine (Endocrinology) and Professor of Cellular And Molecular Physiology at Yale University, to advancement of the understanding of diabetes.
The @EASDnews @novonordiskfond Foundation Prize #Diabetes pic.twitter.com/cE4BHCU46y
— Daniel J Drucker (@DanielJDrucker) August 14, 2025
Key Takeaways
If you’d like to harness insights like these, from granular trial anticipation to emerging clinical themes, our platform CREATION Pinpoint offers end-to-end social intelligence capabilities specifically designed for pharmaceutical leaders. We transform HCP conversation into scalable, strategic intelligence, helping you:
- Prioritise your content and channel activation before, during and after congresses like EASD 2025.
- Rapidly deploy post-congress insights that convert HCP signals into behaviour-shaping assets.
- Track how momentum shifts across themes and therapy areas with near-real-time dashboards and alerts.
- See how your key medical/clinical contacts perform on our unique CREATION Pinpoint impact score, using our DOL Finder platform.
To explore how this applies to your therapeutic area or upcoming congress planning, get in touch with us anytime. We’d be delighted to tailor a demo or overview that aligns with your business goals.
